Art. -Nr.: HY-111140

YS121

Kundenbewertung

Based on 1 Customer Validation

YS121 is a dual inhibitor of microsomal prostaglandin E2 synthase-1 (mPGES-1; IC₅₀ = 3.4 μM) and 5-lipoxygenase (5-LOX; IC₅₀ = 6.5 μM). YS121 exhibits direct, reversible, and specific binding to mPGES-1 (K_D = 10-14 μM). YS121 dose-dependently reduces PGE₂ production with an EC₅₀ of 12 μM in IL-1β-stimulated A549 cells. YS121 (compound 9) activates PPAR-α and -γ (EC₅₀ = 1 and 3.6 μM, respectively). YS121 exhibits anti-inflammatory efficiency in human whole blood as well as in vivo. YS121 can be used for pleurisy research.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.74%
CAS. Nr.: 916482-17-2
Formel: C₂₀H₂₆ClN₃O₂S
Molecular Weight:407.96

Speicherung:

-20°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

YS121 Chemical Structure

CAS. Nr.: 916482-17-2

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

YS121 is a dual inhibitor of microsomal prostaglandin E2 synthase-1 (mPGES-1; IC₅₀ = 3.4 μM) and 5-lipoxygenase (5-LOX; IC₅₀ = 6.5 μM). YS121 exhibits direct, reversible, and specific binding to mPGES-1 (K_D = 10-14 μM)^[1]. YS121 dose-dependently reduces PGE₂ production with an EC₅₀ of 12 μM in IL-1β-stimulated A549 cells^[2]. YS121 (compound 9) activates PPAR-α and -γ (EC₅₀ = 1 and 3.6 μM, respectively)^[3]. YS121 exhibits anti-inflammatory efficiency in human whole blood as well as in vivo. YS121 can be used for pleurisy research^[1].

IC₅₀ & Target

PPAR-α

1 μM (EC₅₀)

PPAR-γ

3.6 μM (EC₅₀)

5-Lipoxygenase

6.5 μM (IC₅₀)

Alle Lipoxygenase Isoform-spezifische Produkte anzeigen :

Alle PPAR Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	12 μM Compound: 2d	Inhibition of mPGES1 in human A549 cells assessed as inhibition of IL-1-beta-induced PGE2 formation by cell-intact assay Inhibition of mPGES1 in human A549 cells assessed as inhibition of IL-1-beta-induced PGE2 formation by cell-intact assay	[PMID: 19053751]
A549	IC₅₀	3.9 μM Compound: 2d	Inhibition of PGES1 in human A549 cell microsome assessed as PGE2 formation by cell-free assay Inhibition of PGES1 in human A549 cell microsome assessed as PGE2 formation by cell-free assay	[PMID: 19053751]
COS-7	EC₅₀	1 μM Compound: 3	Agonist activity at wild-type human PPARalpha LBD expressed in COS7 cells after 12 hrs by Dual-Glo luciferase assay Agonist activity at wild-type human PPARalpha LBD expressed in COS7 cells after 12 hrs by Dual-Glo luciferase assay	[PMID: 25022880]
COS-7	EC₅₀	3.6 μM Compound: 2	Transactivation of human PPARgamma LBD expressed in african green monkey Cos7 cells co-transfected with fused GAL4-DBD after 14 hrs by Dual-Glo Luciferase reporter gene assay Transactivation of human PPARgamma LBD expressed in african green monkey Cos7 cells co-transfected with fused GAL4-DBD after 14 hrs by Dual-Glo Luciferase reporter gene assay	[PMID: 20307981]
COS-7	EC₅₀	3.6 μM Compound: 3	Agonist activity at human PPARgamma LBD expressed in COS7 cells after 12 hrs by Dual-Glo luciferase assay Agonist activity at human PPARgamma LBD expressed in COS7 cells after 12 hrs by Dual-Glo luciferase assay	[PMID: 25022880]
COS-7	IC₅₀	1 μM Compound: 2	Activation of human PPARalpha ligand binding domain expressed in COS7 cells by luciferase reporter gene assay Activation of human PPARalpha ligand binding domain expressed in COS7 cells by luciferase reporter gene assay	[PMID: 25037914]
COS-7	IC₅₀	3.6 μM Compound: 2	Activation of human PPARgamma ligand binding domain expressed in COS7 cells by luciferase reporter gene assay Activation of human PPARgamma ligand binding domain expressed in COS7 cells by luciferase reporter gene assay	[PMID: 25037914]
PMNL	IC₅₀	4.1 μM Compound: 2d	Inhibition of 5-LO in PMNL cells Inhibition of 5-LO in PMNL cells	[PMID: 19053751]

In Vitro

YS121 (0.3-30 μM) acts as a potent and selective inhibitor of mPGES-1 in interleukin-1β-stimulated human A549 cell microsomes, concentration-dependently and non-competitively blocking the conversion of PGH₂ to PGE₂, with no marked inhibition of other PGES enzymes^[1].
YS121 (0.1-30 μM) concentration-dependently inhibits PGE₂ formation with an IC₅₀ value of 3 μM, and moderately suppresses PGE₂ synthesis in the absence of CV4151^[1].
YS121 (0.1-30 μM) inhibits PGE₂ formation without affecting the synthesis of COX-2-derived 6-keto PGF_1α and TxB₂ or COX-1-derived 12-HHT in human whole blood^[1].
YS121 (10 μM, 0-48 h) selectively modulates protein expression over a 48-hour period, specifically reducing COX-2 levels after 24 hours while leaving mPGES-1 expression unchanged^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

interleukin-1β-stimulated human A549 cells
Concentration:

10 μM
Incubation Time:

0, 12, 24, and 48 h
Result:

Decreased the levels of COX-2 after 24 to 48 h in interleukin-1β-stimulated human A549 cells.
Had no significant impact on mPGES-1 expression levels over 48 hours.

In Vivo

YS121 (1.5 mg/kg, i.p., 30 min pre-modeling, once) exhibits potent anti-inflammatory efficacy in a carrageenan-induced rat pleurisy model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male adult Wistar Han rats (200-220 g) injected intraperitoneally with carrageenan^[1]
Dosage:

1.5 mg/kg
Administration:

i.p., 30 min pre-modeling, once
Result:

Significantly inhibited the exudate formation by 62 % and cell infiltration by 40 %.
Reduced the levels of PGE₂, LTB₄ and 6-keto PGF_1α.

Chemical Information

CAS. Nr. 916482-17-2
Appearance Solid
Molecular Weight 407.96
Formel C₂₀H₂₆ClN₃O₂S
Color White to off-white
SMILES

CCCCCCC(SC1=NC(NC2=CC=CC(C)=C2C)=CC(Cl)=N1)C(O)=O
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

-20°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 125 mg/mL (306.40 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.4512 mL

12.2561 mL

24.5122 mL

5 mM

0.4902 mL

2.4512 mL

4.9024 mL

10 mM

0.2451 mL

1.2256 mL

2.4512 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (274 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Koeberle A, et al. The molecular pharmacology and in vivo activity of 2-(4-chloro-6-(2,3-dimethylphenylamino)pyrimidin-2-ylthio)octanoic acid (YS121), a dual inhibitor of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase. J Pharmacol Exp Ther. 2010 Mar;332(3):840-8. [Content Brief]

[2]. Chang HH, et al. Identification and development of mPGES-1 inhibitors: where we are at? Future Med Chem. 2011 Nov;3(15):1909-34.

[3]. Rau O, et al. Alpha-alkyl substituted pirinixic acid derivatives as potent dual agonists of the peroxisome proliferator activated receptor alpha and gamma. Arch Pharm (Weinheim). 2008 Mar;341(3):191-5. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.4512 mL	12.2561 mL	24.5122 mL	61.2805 mL
	5 mM	0.4902 mL	2.4512 mL	4.9024 mL	12.2561 mL
	10 mM	0.2451 mL	1.2256 mL	2.4512 mL	6.1281 mL
	15 mM	0.1634 mL	0.8171 mL	1.6341 mL	4.0854 mL
	20 mM	0.1226 mL	0.6128 mL	1.2256 mL	3.0640 mL
	25 mM	0.0980 mL	0.4902 mL	0.9805 mL	2.4512 mL
	30 mM	0.0817 mL	0.4085 mL	0.8171 mL	2.0427 mL
	40 mM	0.0613 mL	0.3064 mL	0.6128 mL	1.5320 mL
	50 mM	0.0490 mL	0.2451 mL	0.4902 mL	1.2256 mL
	60 mM	0.0409 mL	0.2043 mL	0.4085 mL	1.0213 mL
	80 mM	0.0306 mL	0.1532 mL	0.3064 mL	0.7660 mL
	100 mM	0.0245 mL	0.1226 mL	0.2451 mL	0.6128 mL

Keywords

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

YS121

Covalent Screening Library

Ferroptosis Compound Library

Pyroptosis Compound Library

Anti-Obesity Compound Library

Transcription Factor-Targeted Library

Lipid Metabolism Compound Library

Antidepressant Compound Library

Anti-Prostate Cancer Compound Library

Nuclear Receptor Compound Library

Osteogenesis Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Bioactive Compound Library

Anti-Fibrosis Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Cell Cycle/DNA Damage Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Anti-Aging Compound Library

Alle Lipoxygenase Isoform-spezifische Produkte anzeigen

Alle PPAR Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

YS121

Covalent Screening Library

Ferroptosis Compound Library

Pyroptosis Compound Library

Anti-Obesity Compound Library

Transcription Factor-Targeted Library

Lipid Metabolism Compound Library

Antidepressant Compound Library

Anti-Prostate Cancer Compound Library

Nuclear Receptor Compound Library

Osteogenesis Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Bioactive Compound Library

Anti-Fibrosis Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Cell Cycle/DNA Damage Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Anti-Aging Compound Library

Alle Lipoxygenase Isoform-spezifische Produkte anzeigen

Alle PPAR Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

YS121 Related Classifications

HY-111140 Related Classifications